source
- Lilly reports 79% response rate for FRα-directed ADC in platinum-sensitive ovarian cancerLilly presented phase 1 data on its FRα‑directed antibody‑drug conjugate, sofetabart mipitecan (Sofe-M), combined with bevacizumab in patients whose ovarian cancer had progressed after platinum the…
- Antheia secures $80 million conditional loan from DOD to expand U.S. generic drug manufacturingAntheia, a biosynthesis manufacturer, has been awarded a conditional loan of $80 million from the U.S. Department of Defense. The funding is aimed at onshoring the company’s generic drug productio…